8 powodów, dla których warto stosować lewodropropizynę Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2022
Słowa kluczowe:
lewodropropizyna, kaszel, terapia
##plugins.themes.bootstrap3.article.main##
Abstrakt
Najczęstszą przyczyną ostrego kaszlu są infekcje górnych dróg oddechowych. Kaszel przewlekły może być symptomem wielu innych schorzeń płuc, takich jak: astma oskrzelowa, przewlekła obturacyjna choroba płuc, rak płuca, a także patologii pozapłucnych. Suchy kaszel bywa uciążliwym objawem, który należy ograniczyć, by umożliwić codzienne funkcjonowanie. Nie tylko obniża on jakość życia i snu chorego, ale również wiąże się ze znacznymi kosztami ekonomicznymi. W terapii wykorzystujemy zaledwie kilka substancji czynnych. Jedną z nich jest lewodropropizyna. Poniższa praca omawia jej przydatność kliniczną.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Sapilak , B. J. (2022). 8 powodów, dla których warto stosować lewodropropizynę . Medycyna Faktów , 15(1(54), 72-76. https://doi.org/10.24292/01.MF.0122.10
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Irwin RS, Fletcher KE et al. Evaluation of a Cough-Specific Quality-of-Life Questionnaire. Chest. 2002; 121(4): 1123-31. http://doi.org/10.1378/chest.121.4.1123.
2. Irwin RS, Boulet LP, Cynthia T et al. Managing Cough as a Defense Mechanism and as a Symptom: A Consensus Panel Report of the American College of Chest Physicians. Chest. 1998; 114(2): 133S-81S.
3. Lavezzo A, Melillo G, Clavenna G et al. Peripheral site of action of levodropropizine in experimental induced cough: role of sensory neuropeptides. Pulm Pharmacol. 1992; 5: 143-7.
4. Melillo G, Malandrino S, Rossoni G et al. General pharmacology of the new antitussive levodropropizine. Arzneim Forsch/Drug Res. 1998; 38: 1144-50.
5. Allegra L, Bossi R. Clinical trials with the new antitussive levodropropizine in adult bronchitic patients. Arzneimittelforschung. 1988; 38: 1163-6.
6. Banderali G, Riva E, Fiocchi A. Efficacy and tolerability of levodropropizine and dropropizine in children with non-productive cough. J Int Med Res. 1995; 23: 175-83.
7. De Blasio F, Dicpinigaitis PV, Rubin BK. An observational study on cough in children: epidemiology, impact on quality of sleep and treatment outcome. Cough. 2012; 23: 1.
8. Kim DS, Sohn MH, Jang GC. Levodropropizine in children with bronchitis. Diagn Treatment. 2002; 22: 1029-34.
9. Zanasi A, Lanata L, Fontana G et al. Levodropropizine for treating cough in adult and children: a meta-analysis of published studies. Multidiscip Respir Med. 2015; 10(1): 19. http://doi.org/10.1186/s40248-015-0014-3.
10. Zanasi A, Lanata L, Saibene F et al. Prospective study of the efficacy of antibiotics versus antitussive drugs for the management of URTI-related acute cough in children. Multidiscip Respir Med. 2016; 11: 29. http://doi.org/10.1186/s40248-016-0059-y.
11. Ciprandi G, Licari A, Tosca MA et al. Levodropropizine in children: over thirty years of clinical experience. J Biol Regul Homeost Agents. 2021; 35(4). http://doi.org/10.23812/21-176-L.
12. Rekomendacje 2016 (access: 28.12.2021).
13. De Blasio F, Virchow JC, Polverino MG et al. Cough management: a practical approach. Cough. 2011; 7(1): 7. http://doi.org/10.1186/1745-9974- 7-7.
14. Mannini C, Lavorini F, Zanasi A et al. A Randomized Clinical Trial Comparing the Effects of Antitussive Agents on Respiratory Center Output in Patients With Chronic Cough. Chest. 2017; 151(6): 1288-94. http://doi.org/10.1016/j.chest.2017.02.001.
15. Luporini G, Barni S, Marchi E et al. Efficacy and safety of levodropropizine and dihydrocodeine on nonproductive cough in primary and metastatic lung cancer. Eur Respir J. 1998; 12(1): 97-101. http://doi.org/10.1183/09031936.98.12010097.
16. Bruschi C, Crotti P, Dacosto E et al. Levodropropizine does not affect P0.1 and breathing pattern in healthy volunteers and patients with chronic respiratory impairment. Pulm Pharmacol Ther. 2003; 16(4): 231-6. http://doi.org/10.1016/S1094-5539(03)00053-1.
17. Marseglia GL, Manti S, Chiappini E et al. Acute cough in children and adolescents: A systematic review and a practical algorithm by the Italian Society of Pediatric Allergy and Immunology. Allergol Immunopathol (Madr). 2021; 49(2): 155-69. http://doi.org/10.15586/aei.v49i2.45.
18. Chung KF. Effective antitussives for the cough patient: an unmet need. Pulm Pharmacol Ther. 2007; 20: 438-45.
19. Birring S, de Blasio F, Dicpinigaitis PV et al. Antitussive therapy: A role for levodropropizine. Pulm Pharmacol Ther. 2019; 56: 79-85. http://doi.org/10.1016/j.pupt.2019.03.003.
20. Chung KF. Currently available cough suppressants for chronic cough. Lung. 2008; 186(suppl 1): S82-7. http://doi.org/10.1007/s00408-007-9030-1.
21. Pieragostini L, Cicia S, Banderali G et al. Levodropropizine (LD) efficacy in children affected with pertussis. Abstract – European Pediatric Respiratory Society: IX Meeting, Rome, 27-29.6.1991 Abstract book: P25, 1991.
22. Fiocchi A, Arancio R, Murgo P et al. Levodropropizine effectiveness on nocturnal cough in asthmatic children. Eur Respir J. 1991; 4(suppl 14): 594s.
23. Fiocchi A, Zuccotti GV, Vignati B et al. Valutazione del trattamento con Levodropropizina nelle affezioni respiratorie del bambino. Ped Med Chir (Med Surg Ped). 1989; 11: 519-22.
24. Bizzi G. Impiego di un nuovo preparato antisosse (1-n-fenil-4n) 2,3-diidrossipropil dietilendiamina) nella pratica pediatrica. Gaz Med Ital. 1965; 124: 240-4.
25. Tamburrano D, Romandini S. Studio multicentrico sulla tollerabilità ed efficacia della Levodropropizina un nuovo farmaco antitosse, in una ampia casistica pediatrica. Terapie Essenziali in Clinica. 1989; 4-89: 3-7.
26. Cogo R, Tamburrano D, Romandini S et al. Studio multicentrico sulla efficacia e tollerabilità della levodropropizina, un nuovo farmaco antitosse. Farmaci. 1989; 13: 3-8.
27. Hay AD, Heron J, Ness A; ALSPAC study team. The prevalence of symptoms and consultations in pre-school children in the Avon Longitudinal Study of Parents and Children (ALSPAC): a prospective cohort study. Fam Pract. 2005; 22(4): 367-74. http://doi.org/10.1093/fampra/cmi035.
28. Paul IM. Therapeutic options for acute cough due to upper respiratory infections in children. Lung. 2012; 190(1): 41-4. http://doi.org/10.1007/s00408-011-9319-y.
29. Archer LN, Simpson H. Night cough counts and diary card scores in asthma. Arch Dis Child. 1985; 60(5): 473-4. http://doi.org/10.1136/adc.60.5.473.
30. www.pharmindex.pl www.pharmindex.pl (access: 28.12.2021).
31. Saibene F, Mannini C, Lavorini F et al. Levodropropizine effect on respiratory centre output, a randomized clinical trial. Eur Respir J 2016; 48: PA3549. http://doi.org/10.1183/13993003.congress-2016.PA3549.
2. Irwin RS, Boulet LP, Cynthia T et al. Managing Cough as a Defense Mechanism and as a Symptom: A Consensus Panel Report of the American College of Chest Physicians. Chest. 1998; 114(2): 133S-81S.
3. Lavezzo A, Melillo G, Clavenna G et al. Peripheral site of action of levodropropizine in experimental induced cough: role of sensory neuropeptides. Pulm Pharmacol. 1992; 5: 143-7.
4. Melillo G, Malandrino S, Rossoni G et al. General pharmacology of the new antitussive levodropropizine. Arzneim Forsch/Drug Res. 1998; 38: 1144-50.
5. Allegra L, Bossi R. Clinical trials with the new antitussive levodropropizine in adult bronchitic patients. Arzneimittelforschung. 1988; 38: 1163-6.
6. Banderali G, Riva E, Fiocchi A. Efficacy and tolerability of levodropropizine and dropropizine in children with non-productive cough. J Int Med Res. 1995; 23: 175-83.
7. De Blasio F, Dicpinigaitis PV, Rubin BK. An observational study on cough in children: epidemiology, impact on quality of sleep and treatment outcome. Cough. 2012; 23: 1.
8. Kim DS, Sohn MH, Jang GC. Levodropropizine in children with bronchitis. Diagn Treatment. 2002; 22: 1029-34.
9. Zanasi A, Lanata L, Fontana G et al. Levodropropizine for treating cough in adult and children: a meta-analysis of published studies. Multidiscip Respir Med. 2015; 10(1): 19. http://doi.org/10.1186/s40248-015-0014-3.
10. Zanasi A, Lanata L, Saibene F et al. Prospective study of the efficacy of antibiotics versus antitussive drugs for the management of URTI-related acute cough in children. Multidiscip Respir Med. 2016; 11: 29. http://doi.org/10.1186/s40248-016-0059-y.
11. Ciprandi G, Licari A, Tosca MA et al. Levodropropizine in children: over thirty years of clinical experience. J Biol Regul Homeost Agents. 2021; 35(4). http://doi.org/10.23812/21-176-L.
12. Rekomendacje 2016 (access: 28.12.2021).
13. De Blasio F, Virchow JC, Polverino MG et al. Cough management: a practical approach. Cough. 2011; 7(1): 7. http://doi.org/10.1186/1745-9974- 7-7.
14. Mannini C, Lavorini F, Zanasi A et al. A Randomized Clinical Trial Comparing the Effects of Antitussive Agents on Respiratory Center Output in Patients With Chronic Cough. Chest. 2017; 151(6): 1288-94. http://doi.org/10.1016/j.chest.2017.02.001.
15. Luporini G, Barni S, Marchi E et al. Efficacy and safety of levodropropizine and dihydrocodeine on nonproductive cough in primary and metastatic lung cancer. Eur Respir J. 1998; 12(1): 97-101. http://doi.org/10.1183/09031936.98.12010097.
16. Bruschi C, Crotti P, Dacosto E et al. Levodropropizine does not affect P0.1 and breathing pattern in healthy volunteers and patients with chronic respiratory impairment. Pulm Pharmacol Ther. 2003; 16(4): 231-6. http://doi.org/10.1016/S1094-5539(03)00053-1.
17. Marseglia GL, Manti S, Chiappini E et al. Acute cough in children and adolescents: A systematic review and a practical algorithm by the Italian Society of Pediatric Allergy and Immunology. Allergol Immunopathol (Madr). 2021; 49(2): 155-69. http://doi.org/10.15586/aei.v49i2.45.
18. Chung KF. Effective antitussives for the cough patient: an unmet need. Pulm Pharmacol Ther. 2007; 20: 438-45.
19. Birring S, de Blasio F, Dicpinigaitis PV et al. Antitussive therapy: A role for levodropropizine. Pulm Pharmacol Ther. 2019; 56: 79-85. http://doi.org/10.1016/j.pupt.2019.03.003.
20. Chung KF. Currently available cough suppressants for chronic cough. Lung. 2008; 186(suppl 1): S82-7. http://doi.org/10.1007/s00408-007-9030-1.
21. Pieragostini L, Cicia S, Banderali G et al. Levodropropizine (LD) efficacy in children affected with pertussis. Abstract – European Pediatric Respiratory Society: IX Meeting, Rome, 27-29.6.1991 Abstract book: P25, 1991.
22. Fiocchi A, Arancio R, Murgo P et al. Levodropropizine effectiveness on nocturnal cough in asthmatic children. Eur Respir J. 1991; 4(suppl 14): 594s.
23. Fiocchi A, Zuccotti GV, Vignati B et al. Valutazione del trattamento con Levodropropizina nelle affezioni respiratorie del bambino. Ped Med Chir (Med Surg Ped). 1989; 11: 519-22.
24. Bizzi G. Impiego di un nuovo preparato antisosse (1-n-fenil-4n) 2,3-diidrossipropil dietilendiamina) nella pratica pediatrica. Gaz Med Ital. 1965; 124: 240-4.
25. Tamburrano D, Romandini S. Studio multicentrico sulla tollerabilità ed efficacia della Levodropropizina un nuovo farmaco antitosse, in una ampia casistica pediatrica. Terapie Essenziali in Clinica. 1989; 4-89: 3-7.
26. Cogo R, Tamburrano D, Romandini S et al. Studio multicentrico sulla efficacia e tollerabilità della levodropropizina, un nuovo farmaco antitosse. Farmaci. 1989; 13: 3-8.
27. Hay AD, Heron J, Ness A; ALSPAC study team. The prevalence of symptoms and consultations in pre-school children in the Avon Longitudinal Study of Parents and Children (ALSPAC): a prospective cohort study. Fam Pract. 2005; 22(4): 367-74. http://doi.org/10.1093/fampra/cmi035.
28. Paul IM. Therapeutic options for acute cough due to upper respiratory infections in children. Lung. 2012; 190(1): 41-4. http://doi.org/10.1007/s00408-011-9319-y.
29. Archer LN, Simpson H. Night cough counts and diary card scores in asthma. Arch Dis Child. 1985; 60(5): 473-4. http://doi.org/10.1136/adc.60.5.473.
30. www.pharmindex.pl www.pharmindex.pl (access: 28.12.2021).
31. Saibene F, Mannini C, Lavorini F et al. Levodropropizine effect on respiratory centre output, a randomized clinical trial. Eur Respir J 2016; 48: PA3549. http://doi.org/10.1183/13993003.congress-2016.PA3549.